Horizon 2020
SC1 – Health, Demographic change and Wellbeing - Opportunità per l’area “Salute (2016-2017)”

Caterina Buonocore
Horizon 2020
Punto di Contatto Nazionale SC1
Coordinatore dei PCN in APRE
AGENDA

• Contesto H2020
• Opportunità in Salute
• Programmazione dei prossimi 3 anni di H2020
• National Contact Points
• Grant Offices/uffici brevetti..ecc
H2020/ The Three Pillars

- Excellent science
- Industrial leadership
- Societal challenges
STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?

- **SC1, 2, 3, 7..**
- **SME Instrument**
- **NMP-b**
- **ICT**
- **Materials**

**GROUP of Researchers/actors**
- doing collaborative multidisciplinary research

**GROUP of researchers/actors**
- doing research on Key enabling Technologies

**GROUP of researchers/actors**
- doing basic/visionary but feasible research on technological aspects

**INDIVIDUAL RESEARCHER**
- targeting dev. of research career and training

**INDIVIDUAL RESEARCHER**
- doing High risk/frontier Research

**GROUP of researchers/actors**
- developing solutions close to market

**MSCA**

**ERC**

**FET**

**www.apre.it**
Struttura del programma H2020

**Excellent Science**
- European Research Council
- Frontier research by the best individual teams
- **Future and Emerging Technologies**
  - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
  - Opportunities for training and career development
- **Research infrastructures** (including e-infrastructure)
  - Ensuring access to world-class facilities

**Industrial Technologies**
- **Leadership in enabling and industrial technologies**
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

**Societal Challenges**
- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Secure societies**

**European Institute of Innovation and Technology (EIT)**
- Spreading Excellence and Widening Participation
- Science with and for society
- Joint Research Center (JRC)
2° PILLAR

INDUSTRIAL LEADERSHIP
Connections to Health in Pillar II

**Industrial Technologies**

- Leadership in enabling and industrial technologies
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space

- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation

- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs
[Health opportunities in ICT]

ICT-11-2017: Collective Awareness Platforms for Sustainability and Social Innovation
To demonstrating new forms of bottom-up innovation and social collaboration exploiting digital hyper-connectivity and collaborative tools based on open data, open knowledge, open source software and open hardware.

Proposal may suggest replicable solutions by using existing or very near-to-market technologies. They may ensure strong industrial domain, possibility to embrace cross-domain activities, to demonstrate data harvesting and analytics added value in industrial ecosystems. Possible industrial sectors include health.

Developing and testing protocols for shared space cooperative and collaborative systems leading to viable safety certification standards. Potential proposals may include healthcare and elderly or handicapped care applications.

ICT-30-2017: Photonics KET 2017 (scope b.)
Biophotonics: imaging systems for in-depth disease diagnosis. The objective is the demonstration and validation in real-settings of innovative, easy to operate, compact, and non- or minimally invasive imaging systems to support diagnosis of age and lyfe-style related diseases.

→ Deadline: 25 April 2017
Proposal Template: 70 pages (single step)

Idealist – H2020 ICT/FET NCP Network
http://www.ideal-ist.eu/
Excellent Science
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies
- Leadership in enabling and industrial technologies
- ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

NMP TeAM – H2020 NMP NCP Network
http://www.nmpteam.eu/

ADVANCED MATERIALS AND NANOTECHNOLOGIES FOR HEALTHCARE
(From topics NMBP 12 to 16)

<table>
<thead>
<tr>
<th>Year</th>
<th>Topic</th>
<th>Topic Title</th>
<th>Instrument</th>
<th>TRL</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>NMBP 12-2017</td>
<td>Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices</td>
<td>RIA</td>
<td>4, target 6</td>
<td>1st Stage: 27/10/16 2nd Stage: 4/5/17</td>
</tr>
<tr>
<td></td>
<td>NMBP 13-2017</td>
<td>Cross-cutting KETs for diagnostics at the point-of-care</td>
<td>RIA</td>
<td>3-4-5/6</td>
<td>19/1/17</td>
</tr>
<tr>
<td></td>
<td>NMBP 14-2017</td>
<td>Regulatory Science Framework for assessment of risk benefit ratio of Nanomedicines and Biomaterials</td>
<td>IA</td>
<td>5-6</td>
<td>1st Stage: 27/10/16 2nd Stage: 4/5/17</td>
</tr>
<tr>
<td></td>
<td>NMBP 15-2017</td>
<td>Nanotechnologies for imaging cellular transplants and regenerative processes in vivo</td>
<td>RIA</td>
<td>3-4-5/6</td>
<td>1st Stage: 27/10/16 2nd Stage: 4/5/17</td>
</tr>
<tr>
<td></td>
<td>NMBP 16-2017</td>
<td>Mobilising the European nano-biomedical ecosystem</td>
<td>CSA</td>
<td></td>
<td>19/1/17</td>
</tr>
</tbody>
</table>
3° PILLAR

SOCIETAL CHALLENGES
HEALTH implications in Societal Challenges

- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

Societal Challenges

- Security of Health data
- Management of crisis
- Environment and Health
- Efficient Building / Hospitals
- ICT for HEalth

HEALTH

www.apre.it
Societal Challenge 2 - Food...

Excellent Science
- European Research Council
- Frontier research by the best individual teams
- Future and Emerging Technologies
- Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
- Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies
- Leadership in enabling and industrial technologies
- ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
  - Smart, green and integrated transport
  - Climate action, resource efficiency and raw materials
  - Inclusive, innovative and reflective societies
  - Security society

Healthy and safe foods and diets for all

Linking healthy oceans and seas for healthy people
BG-06-2017: Interaction between people, oceans and seas: a strategic approach towards healthcare and well-being
BG-07-2017: Blue green innovation for clean coasts and seas.
BG-08-2017: Innovative sustainable solutions for improving the safety and dietary properties of seafood

BIO Horizon – H2020 SC2/BIO NCP Network
http://www.ncp-biohorizon.net/start

www.apre.it
## Societal Challenge 7- Security

### Excellent Science
- European Research Council
- Future and Emerging Technologies
- Marie Skłodowska Curie actions
- Research infrastructures (including e-infrastructure)

### Industrial Technologies
- Leadership in enabling and industrial technologies
  - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

### Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

---

### Year | Topic | Topic Title | Instrument | Deadline
--- | --- | --- | --- | ---
2017 | CIP 01- 2016 -2017 | Prevention, detection, response, mitigation of the combination of physical and cyber threats to the critical infrastructure of Europe (including Health Services) | IA | 24/08/17

#### SEREN3– H2020 SC7NCP Network
http://www.seren-project.eu/
SC1. HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING
Work Programme SC1 2016-2017

- Pers. Medicine
- Broad topics
- Less prescriptive topic texts
- Two-year work programme
- Stronger focus on end users
- Clinical trials
Personalised medicine – towards a definition

"Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"
SC1 Work Programme 2017

in brief

Call 'Personalised Medicine'
11 topics

Including 'Coordination activities'
4 topics

- SME Instrument
  2 topics (unchanged from 2016)

- Other Actions
  12 items (incl. InnovFin ID and Birth Day Prize)

€ 486 million

www.apre.it
Health in H2020

- Health solutions can imply different phases of research and innovation
## SC1 topics – 2017

<table>
<thead>
<tr>
<th>Call</th>
<th>Description</th>
<th>Budget</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC1-PM-02-2017</td>
<td><strong>New concepts in patient stratification</strong></td>
<td>€40M</td>
<td>4 Oct. 2016 (1st stage)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>11 Apr. 2017 (2nd stage)</td>
</tr>
<tr>
<td>SC1-PM-03–2017</td>
<td><strong>Diagnostic characterisation of rare disease</strong></td>
<td>€15M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC1-PM-07–2017*</td>
<td><strong>Promoting mental well-being in the young</strong></td>
<td>€20M</td>
<td>4 Oct. 2016 (1st stage)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>11 Apr. 2017 (2nd stage)</td>
</tr>
<tr>
<td>SC1-PM-08–2017</td>
<td><strong>New therapies for rare diseases</strong></td>
<td>€60M</td>
<td>4 Oct. 2016 (1st stage)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>11 Apr. 2017 (2nd stage)</td>
</tr>
</tbody>
</table>

* AMENDED
<table>
<thead>
<tr>
<th>Call</th>
<th>Budget</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SC1-PM-11–2017:</strong></td>
<td>€30M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td>Clinical research on</td>
<td></td>
<td></td>
</tr>
<tr>
<td>regenerative medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personalised coaching</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for well-being and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>care of people as they</td>
<td></td>
<td></td>
</tr>
<tr>
<td>age</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-16–2017:</strong></td>
<td>€19M</td>
<td>14 Mar. 2017</td>
</tr>
<tr>
<td>In-silico trials for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>developing and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>assessing biomedical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>products</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-17 – 2017:</strong></td>
<td>€19M</td>
<td>14 Mar. 2017</td>
</tr>
<tr>
<td>Personalised computer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>models and in-silico</td>
<td></td>
<td></td>
</tr>
<tr>
<td>systems for well-being</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-19–2017:</strong></td>
<td>€8.26M</td>
<td>14 Mar. 2017</td>
</tr>
<tr>
<td>PPI for uptake of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>standards for the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>exchange of digitalised</td>
<td></td>
<td></td>
</tr>
<tr>
<td>healthcare records</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SC1-PM-20-2017:</strong></td>
<td>€9M</td>
<td>11 Apr. 2017</td>
</tr>
<tr>
<td>Development of new</td>
<td></td>
<td></td>
</tr>
<tr>
<td>methods and measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for improved economic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>evaluation and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>efficiency measures in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the health sector</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* AMENDED
### SC1 topics – 2017 – Other actions

<table>
<thead>
<tr>
<th>Call</th>
<th>Budget</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SC1-HCO-08–2017:</strong> Actions to bridge the divide in European health research and innovation</td>
<td>€1M</td>
<td>11 Apr. 2017</td>
</tr>
</tbody>
</table>
| **SMEInst-05-2016-2017:** Supporting innovative SMEs in the healthcare biotechnology sector:  
  a. Cell technologies in medical applications  
  b. Clinical research for the validation of biomarkers and/or diagnostic medical devices* | €53M (2016)  
  €57.3M (2017)** | Multiple cut-off dates in 2016 and 2017 |
| InnovFin Infectious Diseases (InnovFin ID) Pilot | €50M (2016)  
  €50M (2017) | From first quarter of 2016 |
| Inducement prize on reducing maternal and new-born morbidity and mortality - the Birth Day Prize | €1M | 2017 |

---

**SC1 Work Programme** (updated at 25 July 2016)  
Next SC1 Work Programme 2018-2020

VERTICAL themes
1. Personalised medicine
2. Rare diseases
3. Infectious diseases
4. Non-communicable diseases
5. Paediatrics
6. Public health and prevention including migration
7. Active and healthy ageing

HORIZONTAL themes
8. Big data
9. eHealth, mHealth, ICT
10. Integration of care
11. Environment and health, green solutions and sustainability including climate change

CROSS-CUTTING issues
12. Social Sciences and Humanities, integration, inequalities, migration and ethics
13. Sex and gender differences in medicine
14. Commercialisation within “Health, Demographic Change and Well-being”
15. Encouraging stronger and successful involvement of EU-13
SC1 and international cooperation

• Reference to specific multi-lateral initiatives

• Mutual opening of research programmes with Third Countries (USA)

• Funding of Third Countries entities by their own funding agencies for participating to Horizon 2020 (Switzerland, Australia)

• Specific actions
Template for essential information to be provided for proposals including clinical trials / studies / investigations

The use of this template is mandatory for all clinical studies included in a proposal submitted to topics PM-01, PM-02, PM-06, PM-07, PM-08, PM-09, PM-10, PM-11 and HCO-07. For these topics, you will have the possibility to upload the completed template as a separate part of your application in the submission system.

Some advices:

- Proposals containing clinical studies submitted to **topics not listed** can use template as an orientation and provide information in concept and approach or in work packages.
- **Risk and contingency plans** have to be addressed in part B3.2 and table 3.2a.
- Clinical centers whose contribution is limited to **subject recruitment or treatment** may have status of full beneficiary: always preferred!
- **Third parties/subcontractors** must be identified in the DoA.
- **3 unique and exclusive (!) personnel categories**: Doctors, Other medical personnel, Technical personnel. (categories for ‘nurses’ ‘study nurses’ or ‘pharmacists’ do not exist!).

Strategic Initiatives around HEALTH

- Innovative Medicines Initiative 2
  www.imi.europa.eu

- European Innovation Partnership on Active and Healthy Ageing
  https://webgate.ec.europa.eu/eipaha

- Active and Assisted Living 2
  www.aal-europe.eu

- European & Developing Countries Clinical Trials Partnership (EDCTP2)
  www.edctp.org
IMI 2 budget

€3.276 bn

Partnership 2014 - 2024

€1.638 bn

EFPIA = European Federation of Pharmaceutical Industries and Associations

* Imaging, Diagnostics, IT for health etc.
The IMI portfolio

**Corporate contribution**  **IMI funding**

- **€ 756 906 619**  
  Infectious diseases - 39%

- **€ 213 636 872**  
  Drug discovery - 11%

- **€ 186 102 324**  
  Brain disorders - 10%

- **€ 118 189 462**  
  Metabolic disorders - 6%

- **€ 116 287 312**  
  Drug safety - 6%

- **€ 76 872 548**  
  Stem cells - 4%

- **€ 74 345 401**  
  Data management 4%

- **€ 74 004 854**  
  Cancer

**Partners**

- AiCuris
- Animal Health
- Division of Sanofi
- Astellas
- AstraZeneca
- Basilea
- Boehringer Ingelheim
- Cubist
- GSK
- Janssen
- Lundbeck
- Merck
- Novartis
- Pfizer
- Remex
- Sanofi
- Johnson & Johnson
- Medimmune
- Merck
- Merck Sharp & Dohme Corp
- Merial
- Novartis
- Pfizer
- Remex
- Sanofi

**Total**  

**€ 1 952 573 292**
Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes/Metabolic disorders
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines
A Typical IMI Consortium

Private Investment
*in kind*
(€ 1 billion)

EU Public Funding
*cash*
(€ 1 billion)

EFPIA

Pharma 1
Pharma 2
Pharma 3
Pharma 4
Pharma 5
Pharma 6

ACADEMIA

PATIENTS’ ORGANISATIONS

HOSPITALS

SMALL AND MEDIUM-SIZED ENTERPRISES

REGULATORS

www.apre.it
Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (≤ €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- EU Member States
- Associated Countries

Other countries:
No funding unless
- participation deemed essential by IMI for carrying out the action
- Annual Work Plan / Calls documents

New! At least three legal entities
IMI 2 – Call 8 includes the following topic:

- **Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks**

The indicative budget for the entire period of 2 years is €70 million.

IMI 2 – Call 10 will includes the following topics:

Foreseen launch **Autumn 2016:**

- **Understanding hypoglycaemia:** the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
- How **big data** could support better diagnosis and treatment outcomes for **prostate cancer**
- Improving the care of patients suffering from **acute or chronic pain**
- Creation of a pan-European **paediatric clinical trials** network
- **Biomanufacturing 2020:** Development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
- Unlocking the **solute carrier gene-family** for effective new therapies
- Enhanced **patient voice** in medicines lifecycle
- Precision medicines approaches in **autism spectrum disorders**
Stay in touch

- Visit our website www.imi.europa.eu
- Sign up to our newsletter bit.ly/IMInewsletter
- Follow us on Twitter @IMI_JU
- Join our LinkedIn group bit.ly/LinkedInIMI
- E-mail us infodesk@imi.europa.eu
DG SANCO
Third Health Programme 2014-2020
Il programma si concentra su **quattro obiettivi principali**, il cui scopo è conseguire un forte potenziale di crescita economica grazie al miglior stato di salute:

1) **Sviluppare strumenti e meccanismi comuni a livello dell'UE per affrontare la carenza di risorse umane e finanziarie, al fine di contribuire a sistemi sanitari innovativi e sostenibili;**

2) **Migliorare l'accesso alle competenze mediche e alle informazioni concernenti patologie specifiche anche su scala transnazionale e sviluppare soluzioni condivise e orientamenti per migliorare la qualità della sanità e della sicurezza dei pazienti.**

3) **Individuare, diffondere e promuovere l'adozione di buone pratiche convalidate per prevenire le malattie e promuovere la buona salute.**

4) **Sviluppare approcci comuni per proteggere i cittadini dalle minacce sanitarie transfrontaliere.**

La partecipazione è aperta ad una vasta gamma di organizzazioni, tra cui:

- Gli Istituti di Ricerca, Università e Ospedali
- Gli enti pubblici
- ONG
- Imprese Commerciali

The EU grant is limited to a maximum co-funding rate of 60% of eligible costs. In case of exceptional utility up to 80% can be granted (see Work Plan 2016, Annex VII).

Le dotazioni finanziarie per l'attuazione del programma per il periodo dal 1° gennaio 2014 al 31 dicembre 2020 ammontreranno a 449,4 milioni di EUR.
### Scaduto

**Deadline: 2\textsuperscript{nd} June 2016**

<table>
<thead>
<tr>
<th>TITLE</th>
<th>INDICATIVE AMOUNT, EUR</th>
<th>Ref. in Work Plan 2016</th>
<th>Grants foreseen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migrants’ health: Best practices in care provision for vulnerable migrants and refugees</td>
<td>4.500.000</td>
<td>2.1.1.1</td>
<td>one or more</td>
</tr>
<tr>
<td>Gathering knowledge and exchanging best practices on measures reducing underage drinking and heavy episodic drinking</td>
<td>1.200.000</td>
<td>2.1.1.2</td>
<td>one or more</td>
</tr>
<tr>
<td>Gathering knowledge and exchanging best practises to on measures to prevent illicit drug use in line with the minimum quality standards in drug demand reduction</td>
<td>600.000</td>
<td>2.1.1.3</td>
<td>one or more</td>
</tr>
<tr>
<td>Support to Member States and stakeholders to address the chronic disease challenge</td>
<td>2.500.000</td>
<td>2.1.1.4</td>
<td>one or more</td>
</tr>
<tr>
<td>Donor selection and protection</td>
<td>550.000</td>
<td>2.1.4.3</td>
<td>one or more</td>
</tr>
</tbody>
</table>
Come partecipare?

Vi interessa partecipare al programma per la salute? Tutte le informazioni, insieme al modulo di candidatura, sono disponibili qui: Agenzia Esecutiva per i Consumatori, Salute, Agricoltura e Alimentazione - CHAFEA

Il referente nel nostro paese

Contattate il referente nel vostro paese per ottenere assistenza e consigli:

Punto focale nazionale
Dr Giovanni NICOLETTI
Ministero della Salute
nfp_eahc@sanita.it

Per ulteriori informazioni:
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/hp/
Active & Healthy Ageing

A European Innovation Partnership
European Innovation Partnership on Active & Healthy Ageing

crosscutting, connecting & engaging stakeholders across sectors, from private & public sector

+2 HLY by 2020
*Triple win for Europe*

**Sustainable & efficient care systems**
- Health & quality of life of European citizens
- Growth & expansion of EU industry

**Pillar I**
- Prevention
- Screening early diagnosis

**Pillar II**
- Care & cure

**Pillar III**
- Independent living & active ageing

**Action Groups**
- Improving prescriptions and adherence to treatment
- Better management of health: preventing falls
- Preventing functional decline & frailty
- Integrated care for chronic conditions, inc. telecare
- ICT solutions for independent living & active ageing
- Age-friendly cities and environments
I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione.

- **Action Group A1:** Prescription and adherence action at regional level.
- **Action Group A2:** Personalized health management: Falls prevention.
- **Action Group A3:** Prevention of functional decline and frailty.
- **Action Group B3:** Integrated care for chronic diseases, including remote monitoring at regional level.
- **Action Group C2:** Interoperable independent living solutions.
- **Action Group D4:** Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed Action Groups through the "Invitation for Commitment" application process.

In each Action Group, stakeholders commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.
E' attivo online anche un "**Marketplace per idee innovative**", che rientra in EIP.

**E' uno spazio interattivo per scambiare opinioni, trovare partners o iniziative al fine di mettere in pratica delle idee innovative:**

https://webgate.ec.europa.eu/eipaha/

**Per ulteriori Informazioni:**
http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing
<table>
<thead>
<tr>
<th>Program</th>
<th>Description</th>
<th>Participants</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-Rare-3</td>
<td>ERA-NET rare disease research implementing IRDiRC objectives</td>
<td>AGENCE NATIONALE DE LA RECHERCHE</td>
<td>FR</td>
</tr>
<tr>
<td>ERACoSysMed</td>
<td>ERACoSysMed - Collaboration on systems medicine funding to promote the implementation of systems biology approaches in clinical research and medical practice</td>
<td>FORSCHUNGSZENTRUM JUELICH GMBH</td>
<td>DE</td>
</tr>
<tr>
<td>JPco-fuND</td>
<td>ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020</td>
<td>INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)</td>
<td>FR</td>
</tr>
<tr>
<td>TRANSCAN-2</td>
<td>ERA-NET: Aligning national/regional translational cancer research programmes and activities</td>
<td>MINISTERO DELLA SALUTE</td>
<td>IT</td>
</tr>
<tr>
<td>ERA-CVD</td>
<td>ERA-NET on cardiovascular diseases to implement joint transnational research projects and set up international cooperations</td>
<td>DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV</td>
<td>DE</td>
</tr>
<tr>
<td>JPI-EC-AMR</td>
<td>ERA-NET for establishing synergies between the Joint Programming Initiative on Antimicrobial Resistance Research and Horizon 2020</td>
<td>VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL</td>
<td>SE</td>
</tr>
<tr>
<td>NEURON Cofund</td>
<td>ERA NET NEURON in the area of brain-related diseases and disorders of the nervous system</td>
<td>DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV</td>
<td>DE</td>
</tr>
</tbody>
</table>
### Complessivo SC1 Bandi 2014-2015-2016

<table>
<thead>
<tr>
<th>No. topics</th>
<th>Budget Mill. EUR</th>
<th>Proposte presentate</th>
<th>Proposte finanziate</th>
<th>Tasso di successo</th>
</tr>
</thead>
<tbody>
<tr>
<td>72</td>
<td>1.438,7</td>
<td>2.806</td>
<td>257</td>
<td>9,15%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Partecipazione</th>
<th>No. Partecipanti italiani in proposte presentate</th>
<th>No. Partecipanti italiani finanziati</th>
<th>Tasso di successo partecipanti Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.061</td>
<td>274</td>
<td>8,9%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinamento</th>
<th>No. Proposte presentate a coordinamento italiano</th>
<th>No. Coordinamenti italiani finanziati</th>
<th>Tasso di successo coordinatori Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>375 (13,3% del totale EU)</td>
<td>18</td>
<td>4,8%</td>
</tr>
</tbody>
</table>
Proseguiamo ...

APRE
Agenzia per la Promozione della Ricerca Europea
via Cavour, 71
00184 - Roma
www.apre.it
Tel. (+39) 06-48939993
Fax. (+39) 06-48902550